Background: Idiopathic basal ganglia calcification (IBGC) is a genetic disorder characterized by bilateral basal ganglia calcification and neural degeneration. In this study, we reported a new SLC2OA2 mutation of IBGC and reviewed relevant literature to explore the association between phenotypes and genotypes in Chinese IBGC patients. Methods: Clinical information of the proband and her relatives were collected comprehensively. Blood samples of both the patient and her father were obtained, and genetic screening related to IBGC was performed using second generation sequencing with their consent. Findings were confirmed by Sanger sequencing. Polyphen-2 was used to predict the potential association between mutations and disease. Then, we retrieved literatures of Chinese IBGC patients and explored the association between phenotype and genotype. Results: A novel mutation was identified through genetic testing, and it is suggested to be a damage mutation predicted by Polyphen-2. Through literature review, we found that SLC20A2 mutation is the most common cause for IBGC in China. Its hot spot regions are mainly on the 1 st and 8 th exons; the second common one is PDGFB where the hot spot covered a length of 220-230 bp localized on the 2 nd exon; moreover, Chinese IBGC patients featured early-onset, more severe movement disorder and relatively mild cognitive impairment compared with those in other countries. Conclusions: There is significant heterogeneity both in phenotype and genotype in Chinese IBGC patients. Further research of pathogenic mechanism of IBGC is required to eventually develop precise treatment for individuals who suffered this disease. This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
IntroductIon
Idiopathic basal ganglia calcification (IBGC) is an autosomal dominant inherited disease characterized by neural degeneration and basal ganglia calcification. IBGC is clinically heterogeneous, manifesting a variety of symptoms including but not limited to movement disorders, cognitive impairment, and psychiatric symptoms. The radiological features are central neural system calcification mainly affecting bilateral basal ganglia, cerebellar dentate nuclei, and subcortical areas. Pathological findings are calcium accumulation around arteriole and small vessels. [1] IBGC now has five types, except for children IBGC, others are all adult onset. There are four causal genes identified so far, including solute carrier family 20 member 2 (SLC20A2), platelet-derived growth factor receptor beta (PDGFRB), platelet-derived growth factor subunit B (PDGFB), xenotropic and polytropic retrovirus receptor 1 (XPR1). [2] In this study, we reported a familial IBGC pedigree caused by a novel SLC20A2 mutation. Furthermore, we reviewed literature clinical characteristics of different genotype, aiming to help clinical diagnosis.
Methods

Ethical approval
All subjects signed informed consent for genetic testing, and the study was approved by the Ethics Committee of Xuanwu Hospital, Capital Medical University, China.
Clinical information collection
Clinical information of the proband was comprehensively collected, including detailed symptoms, family history, physical examination, laboratory tests results, and cranial radiological scan. Some of the family members underwent computed tomography (CT) scan. Battery of routine laboratory tests was performed to exclude other causes of basal ganglia calcification. Family members were considered as affected members when there are similar clinical characteristics and imaging results. Family members lacking clinical characteristics of IBGC and cerebral calcification are considered as probable unaffected members of the family.
Gene sequencing and mutation prediction
Blood samples of both the proband and her father were obtained and genetic testing covering 192 relevant genes was performed. Polyphen-2 (http://genetics.bwh.harvard. edu/pph2/) was used to predict possible association between the mutation and disease.
Literature retrieve
We retrieved literatures of IBGC of Chinese patients in PubMed published before October 1, 2017, and analyzed to look for the association between phenotype and genotype, aiming to help clinical diagnosis.
results
Clinical information
The proband of this pedigree is 52-year-old woman [ Figure 1 , II-5]. Her chief complaints were as follows paroxysmal tics, progressive memory loss, and bilateral upper limb spasm for 6 months. She was admitted to our hospital on February 15, 2017. Two years ago, she had paroxysmal tics without conscience loss, presenting as limb spasm, which lasted for about 2 min and then relieved by itself. After then, this kind of symptom has never presented again. However, her memory started to decline since then. One year ago, she complained a significant memory loss, such as she could not find household items living stuffs and she had difficulty in finding way home. The symptoms mentioned above continued to worsen. She developed speaking difficulties. In addition, she also experienced muscle tics in her hands lasting about 2 min and then the symptoms alleviated on their own. Ictal frequency was about 2-3 times a week. Consciousness was retained during ictal period. 
Physical examination
Laboratory test results
Laboratory tests were performed to exclude other causes of basal ganglia calcification. Serum calcium was 2.21 mmol/L (reference range: 2.03-2.67 mmol/L). Serum phosphorus was 1.32 mmol/L (reference range: 0.84-1.65 mmol/L). Twenty-four hours urine calcium and phosphorus values were normal. Blood parathyroid level was normal. Other laboratory tests including blood routine, biochemistry, immunology, and paraneoplastic tests were within normal ranges. CT scan showed bilateral symmetric basal ganglia calcification [ Figure 2b ]. We excluded hyperthyroidism and other causes of abnormality of metabolism of calcium and phosphorus.
Pedigree description
Retrieving her family history, we found that her father appeared dementia in his 70s, his CT scan shown bilateral basal ganglia calcification [ Figure 2a ]. Her mother and elder brother were shown no abnormality. Her little sister died of convulsion in 2 years old; however, there was no positive imaging result left shown she was affected. Her brother presented no symptom while his CT image shown similar calcification lesion in brain. Important information about the proband and other affected and unaffected members is shown in Table 1 .
Genetic sequencing and function prediction
Sequencing results of the patients were compared with those of 1000 normal people, and a new SLC20A2 missense mutation was found, c.248C>T, p.Thr83Met in both her and her father's blood DNA samples. Due to the absence of II-3, II-6 of the family, we could not further confirm cosegregation within the family by genetic sequencing. Instead, we used Polyphen 2 (http://genetics.bwh.harvard.edu/pph2/) to predict the likelihood of this mutation interfering with the normal protein function. Interestingly, it was shown to be probably damaging [ Figure 3 ].
Clinical characteristics of other genotypes
SLC20A2-related IBGC was the most frequent cause in both familial and sporadic IBGC, accounting for about 40-50% in the whole single-gene caused IBGC. [3, 4] The typical characteristics of SLC20A2-related IBGC patients in the Chinese population including pedigree in this study featured early onset and paroxysmal movement disorder. [5] Cognitive impairment was much milder in most patients compared with patients of other counties. As shown in Table 2 , there has been reported about 40% mutation found within the 8 th exon, the next is the 1 st exon, accounting for about 30%.
PDGFB gene was the second cause of single gene IBGC. [10, 11] The typical clinical characteristics were much milder compared with those carried SLC20A2 mutations, which feature movement disorder and atypical symptoms such as headache slight memory decline and mutations of PDGFB mainly focused on the region of the 2 nd exon covering a length of 220-230 bp [ Table 3 ].
As for other genotypes, there were only 2 PDGFRB-positive cases in a screen among Chinese patients of non-SLC20A2 and non-PDGFB. [14] XPR1-related IBGC has not found in China yet.
dIscussIon
In this study, we found a novel SLC20A2 mutation of IBGC. SLC20A2-related IBGC was the most common cause in familial and sporadic IBGC, accounting for about 40-50% of IBGC cases caused by a single gene. [3, 4] According to Human Gene Mutation Database, there are 50 mutations in SLC20A2 associated with IBGC, most of which are localized in the 8 th exon. [1, 4, 5, [7] [8] [9] [15] [16] [17] [18] In China, the most frequent single-gene IBGC reported was SLC20A2-related IBGC. [5, [7] [8] [9] 18 ] SLC20A2 gene encodes for sodium-dependent phosphate transporter 2, a membrane carrier of phosphorus mainly expressed at basal ganglia and cerebellum where calcium accumulation was most significant. [19] The 8 th exon encodes for the motif related to binding and transporting phosphate. Mutations leading to amino acid sequence changes might impair the function of phosphate transportation process and cause local/focal extracellular calcification, which is the production of the combination of calcium ion and phosphate deposits. [7, [20] [21] [22] Local calcification influence not only function of local areas but also function of other related areas through brain connection, which was considered as a plausible mechanism underlying movement disorder and cognitive and psychiatric symptoms seen in patients. [23, 24] Due to the different pathogenicity caused by different types of mutations and resilience ability of individuals, clinical manifestations varied significantly, even in the same pedigree in which individuals shared the same causing mutation, they might present with totally different penetrance, expressivity, and symptoms. [25] However, in general, there are three common symptoms -movement disorder, psychiatric symptoms, and cognitive impairment, appearing in about 50-60% patients. [1] The relatively typical characteristics of SLC20A2-related IBGC in Chinese population including the pedigree in this study are early onset and paroxysmal b a movement disorder. [5] Cognitive impairment in most patients is much milder compared with patients of other countries. Other symptoms are migraine and epilepsy. [5] [6] [7] [8] Within pedigrees, radiological calcification might appear before clinical symptoms, but there was a positive relationship between severity of clinical symptoms and radiological calcification degree. While among pedigrees, there were huge differences in onset age, symptom severity, and types of symptoms. It has been reported about 40% mutation found within the 8 th exon; the next is the 1 st exon, accounting for about 30%, as it shown in Table 2 . Hence, we could postulate that the 1 st and the 8 th exons might hot region of this disease.
PDGFB gene is the second common cause of single-gene IBGC, [10, 11] and was first reported by Keller et al. [26] PDGFB gene plays a crucial role in the development of blood-brain barrier (BBB). Mutations causing loss of function of the gene results in disrupted BBB, which in turn leads to abnormality of metabolism of calcium and phosphate. [26, 27] PDGFB-related cases are much more rare compared with SLC20A2 ones. There are only two relevant reports. [12, 13] The typical clinical symptoms are much milder than those carrying SLC20A2 mutations, and movement disorder and atypical symptoms such as headache and slight memory decline are frequently observed. As for mutations in PDGFB, most mutations are located in the region of the 2 nd exon covering a length of 220-230 bp, indicating that the 2 nd exon was possibly a hot region for this disease. However, due to the paucity of reported cases, this speculation needs to be further confirmed in a larger cohort.
PDGFRB mutation is a newly discovered cause of IBGC and is relatively rare compared with the two above. The first case was not reported until 2013. [28] PDGFRB gene encodes for a subunit of platelet-derived growth factor receptor coupled with tyrosine kinase. Mutations in PDGFRB results in loss of function of the receptor, which places a detrimental impact on intracellular signaling transduction during the development of BBB and/or other processes, ultimately leading to disturbance of calcium and phosphate metabolism. [29] There were only 2 PDGFRB-positive cases in a screen among Chinese patients of non-SLC20A2 and non-PDGFB, which implied that PDGFRB mutation was not common in Chinese patients with IBGC. [14] To sum up, mutations in SLC20A2 gene are the most common cause of IBGC in China, and the hot region for mutations are 1 st and 8 th exons. The second common cause is PDGFB, which has a mutational hot spot covering a length of 220-230 bp on the 2 nd exon. Based on clinical manifestation among these patients, we concluded that Chinese IBGC patients with mutations mentioned above feature early onset and predominant paroxysmal movement disorder. Cognitive impairment is much milder. Moreover, other atypical symptoms such as headache and depression are frequently seen. Even so, there are significant differences from the range of severity to clinical manifestations both within and among pedigrees. In addition, SLC20A2-related IBGC accounts for about 40-50% among all these patients based on literature. PDGFB only explains a small proportion about 10%. [11] While a study of genetic screen among Chinese IBGC patients, without SLC20A2 or PDGFB showed merely 1.4% positive rate of all these IBGC patients. [14] So what about those negative patients? How many genes related to IBGC are unknown? And what is the exact pathology [6, 7] 36 Headache, depression c.1492G>A, p.Gly498Arg 6 th exon Pedigree [7] 1 Epilepsy, mental retardation, parkinsonism, ataxia c.1802C>G, p.Ser601Trp 8 th exon
Pedigree [7] --c.1802C>T, p.Ser601Leu 8 th exon Pedigree [8] Depression c.510delA, p.R172fsX19 2 nd exon Pedigree [9] 13 Repeat c.185T>C, p.Leu62Pro 1 st exon Pedigree [9] 27 Dystonia c.935-1G>A Upstream of the 8 th exon Sporadic [9] 21
Involuntary movement c.1470_1478delGCAGGTCCT p.Gln491_Leu493del 7 th exon Sporadic [9] Headache c.82G>A, p.Asp28Asn 1 st exon Pedigree [5] 12
Paroxysmal movement disorder c. Pedigree [12] 12 Paroxysmal movement disorder c.232C>T, p.Arg78Cys 2 nd exon Sporadic [12] 33
Dazzle c.220G>T, p.Glu74* 2 nd exon Sporadic [13] 30
Headache c.232C>T, p.Arg78Cys 3 rd exon p.Glu74*: 220G>Tisa premature termination codon mutation causing premature transcription termination. IBGC: Idiopathic basal ganglia calcification; PDGEB: Platelet derived growth factor subunit B.
behind these reported mutations? If there could been curable method for these patients. All these questions need to be further explored either clinically or genetically. The clearer our understanding of the pathological courses is, the more likely a cure would be found.
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